BMS, SOMERSET TEAM UP TO DISTRIBUTE EMSAM FOR MAJOR DEPRESSIVE DISORDER

Bristol-Myers Squibb Company and Somerset Pharmaceuticals, a joint venture between Mylan Laboratories and Watson Pharmaceuticals, have entered into an agreement for the commercialization and distribution of Somerset's Emsam (selegiline transdermal system), an investigational monoamine oxidase inhibitor administered as a transdermal patch for the acute and maintenance treatment of patients with major depressive disorder.

Pharmabiz.com (http://www.pharmabiz.com/article/detnews.asp?articleid=25431)